GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Net Current Asset Value

Asensus Surgical (Asensus Surgical) Net Current Asset Value : $0.04 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Asensus Surgical's net current asset value per share for the quarter that ended in Dec. 2023 was $0.04.

The historical rank and industry rank for Asensus Surgical's Net Current Asset Value or its related term are showing as below:

ASXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.16   Med: 6.07   Max: 15.88
Current: 6.09

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Asensus Surgical was 15.88. The lowest was 1.16. And the median was 6.07.

ASXC's Price-to-Net-Current-Asset-Value is ranked worse than
57.48% of 588 companies
in the Medical Devices & Instruments industry
Industry Median: 5.05 vs ASXC: 6.09

Asensus Surgical Net Current Asset Value Historical Data

The historical data trend for Asensus Surgical's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Net Current Asset Value Chart

Asensus Surgical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.15 0.41 0.30 0.04

Asensus Surgical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.23 0.16 0.09 0.04

Competitive Comparison of Asensus Surgical's Net Current Asset Value

For the Medical Devices subindustry, Asensus Surgical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asensus Surgical's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's Price-to-Net-Current-Asset-Value falls into.



Asensus Surgical Net Current Asset Value Calculation

Asensus Surgical's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(36.386-25.672-0-0)/264.922
=0.04

Asensus Surgical's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(36.386-25.672-0-0)/264.922
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asensus Surgical  (AMEX:ASXC) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Asensus Surgical Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Asensus Surgical (Asensus Surgical) Business Description

Traded in Other Exchanges
Address
1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Executives
Starling William N Jr director 2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi director C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert director 343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J. officer: Chief Technology Officer 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze officer: EVP, Chief Financial Officer C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh officer: Interim CFO 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery officer: EVP and CFO C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith officer: Chief Commercial Officer 7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope director, officer: President and CEO C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a 10 percent owner VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Asensus Surgical (Asensus Surgical) Headlines

From GuruFocus

TransEnterix and Butterfly Among Medtech M&A Opportunities

By Barry Cohen Barry Cohen 12-23-2020